Medical/Pharmaceuticals

Norgine welcomes TGA registration in Australia of PEDMARQSI® (sodium thiosulfate anhydrous) for the prevention of cisplatin-induced hearing loss in children1

* PEDMARQSI® is now TGA registered in Australia for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to <18 years of age with localised, non-metastatic, solid tumours * TGA registration provides an approved treatment option in an area of significant unmet me...

2026-05-06 05:01 3547

BGM0504 Achieves 19.3% Robust Weight Reduction, 16.5 cm Waist Circumference Decrease, Significant SBP/DBP Improvements of 22.9/12.9 mmHg, and 70.7 μmol/L Uric Acid Reduction; Phase III Trial Meets Primary Endpoint and All Key Secondary Endpoints

SUZHOU, China, May 5, 2026 /PRNewswire/ -- BrightGene Bio-Medical Technology Co., Ltd. (hereinafter referred to as " BrightGene Bio-Medical" or "the Company") announced that its proprietary GLP-1 (glucagon-like peptide-1)/GIP (glucose-dependent insulinotropic polypeptide) dual receptor agonist, B...

2026-05-05 20:20 3462

Samsung Biologics Listed on Dow Jones Best-in-Class World Index for Fifth Consecutive Year

* Marks five consecutive years of inclusion, reflecting continued progress in ESG management and execution * Recognition highlights proactive alignment with evolving expectations from global stakeholders INCHEON, South Korea, May 5, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a l...

2026-05-05 19:00 5697

Senhwa Biosciences Launches Global Study, Targeting Breakthrough in Hard-to-Treat Cancers with CX-5461 and Tislelizumab Combination

TAIPEI and SAN DIEGO, May 5, 2026 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company today announced the initiation of a global,multi-center clinical trial. The Company has also submitted an Investigational New Drug (IND) application to the U.S. Food...

2026-05-05 15:40 4789

Restore Vision Announces First-in-Human Clinical Interim Results for RV-001, a GPCR-Based Optogenetic Gene Therapy

* Phase I/II clinical trial interim results, out to 168 days, from the two RV-001 dosing cohorts with advanced Retinitis Pigmentosa are presented at key May 2026 meetings: Eyecelerator and Retinal Therapeutics Innovation Summit. * No dose-limiting toxicities (DLTs) or drug-related serious adve...

2026-05-01 14:30 11009

Bambusa Therapeutics Completes Patient Enrollment in the Phase 1b/2a Trial Evaluating BBT001 as a Treatment for Atopic Dermatitis

- Bambusa's lead product candidate, BBT001 is a next-generation long-acting bispecific antibody targeting two clinically and commercially validated targets, IL-4Rα and IL-31 for the treatment of atopic dermatitis (AD) and other type 2 inflammatory skin diseases - - Bambusa plans to announce topl...

2026-04-30 20:00 5816

Formosa Pharmaceuticals and Singapore Eye Research Institute (SERI) Partner to Advance Novel Ophthalmic Formulations for Corneal Diseases

SINGAPORE and TAIPEI, April 30, 2026 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. ("Formosa", 6838.TW) and the Singapore Eye Research Institute ("SERI") are pleased to announce a strategic research collaboration to develop next-generation ophthalmic formulations. This partnership will leverage ...

2026-04-30 14:30 6608

New Classification System of Malocclusions Published in the Journal of Aligner Orthodontics (JAO) by Prof. Gang Shen's Team

SHANGHAI, April 30, 2026 /PRNewswire/ -- A seminal research paper titled "A New Classification System for Malocclusions with Facial Convexity"has been officially published in the 2026 Volume 1 issue of the Journal of Aligner Orthodontics (JAO). This article, authored by Professor Gang Shen and hi...

2026-04-30 13:33 5469

2026 ESMO GC | Mabwell to Present Latest Clinical Data on 9MW2821 for Cervical Cancer in Oral and Poster Presentations

SHANGHAI, April 30, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, today announced that two latest clinical study results of its novel Nectin‑4 targeting ADC (R&D code: 9MW2821) in cervical cancer will be ...

2026-04-30 12:26 6043

New study demonstrates up to 73% reduction in genome analysis errors using AI-trained models versus standard approaches

SAN JOSE, Calif., April 29, 2026 /PRNewswire/ -- Complete Genomics , a U.S.-based leader in genomic sequencing technologies, todayannounced results demonstrating that AI-trained variant calling mode...

2026-04-29 23:02 5689

WuXi Biologics Releases 2025 Sustainability Report, Advancing Sustainable Growth and Improving Healthcare Access

* Contributing to the United Nations Sustainable Development Goals, driving equitable access to healthcare through technology and innovation * Enhancing governance transparency and effectiveness to create long-term value for all stakeholders * Empowering employees and fostering shared value ...

2026-04-29 20:30 5192

Vivacta Bio Closed Series A and Series A+ Financing of Over US$50 Million

Backed by Decheng Capital, Loyal Valley Capital, OrbiMed, and Other Renowned Investors SHANGHAI, April 29, 2026 /PRNewswire/ -- Vivacta Biotechnology (Shanghai) Co., Ltd. ("Vivacta" or "Vivacta Bio"), an innovative biotechnology company focused on revolutionizing in vivo CAR-T therapies, announc...

2026-04-29 20:15 3533

United Imaging Healthcare Releases 2025 Annual Report and Q1 2026 Results, Delivering Strong Growth with Accelerated Global Expansion

SHANGHAI, April 29, 2026 /PRNewswire/ -- United Imaging Healthcare (688271.SH),a global innovator in advanced medical imaging technologies and intelligent healthcare solutions, announced its 2025 annual results and Q1 2026 performance, both delivering solid growth. In 2025, the company reported ...

2026-04-29 20:00 5513

United Imaging Healthcare Releases 2025 ESG Report: Upgraded to MSCI "AA" Rating, Driving Sustainable Development Through Innovation

SHANGHAI, April 29, 2026 /PRNewswire/ -- United Imaging Healthcare (SSE:688271) has released its 2025 Environmental, Social and Governance (ESG) Report, outlining the company's strategic framework, key initiatives, and long-term commitments across sustainability. Over the past year, the company ...

2026-04-29 20:00 5278

ESG | HitGen Releases 2025 Sustainability Report

CHENGDU, China, April 29, 2026 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) released its 2025 Sustainability Report on April 29, 2026. This report is the second sustainability report of HitGen, aiming to present the Company's philosophies and polic...

2026-04-29 19:00 4562

Insilico's Rentosertib Inhalation Solution Receives IND Clearance for the World's First AI-Driven Candidate to Enter Direct-to-Lung Clinical Study

* Following positive Phase IIa results for oral Rentosertib in GENESIS-IPF with good tolerability, a favorable PK profile, and dose-dependent efficacy improvements, the inhalation solution has received IND clearance from the CDE. * The inhalation solution is designed for targeted lung delivery...

2026-04-29 09:00 5134

Alma Unveils Longevity Approach at Alma Academy, Advancing Long-Term Skin Performance

CAESAREA, Israel, April 29, 2026 /PRNewswire/ -- Alma , a Sisram Medical company and a global leader in medical aesthetic solutions, unveiled its longevity strategy at its global Alma Academy, outlining its shift toward a continuous care model and a new long-term growth a...

2026-04-29 08:30 3527

Piramal Pharma Limited Announces Results for Q4 and Full-year FY26

MUMBAI, India, April 28, 2026 /PRNewswire/ -- Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceutical, health and wellness company, today announced its standalone and consolidated results for the Fourth Quarter (Q4) and Full-year ended 31st March 2026. Consolidated...

2026-04-29 03:51 4816

ACROBiosystems Wins CiteAb Award, Gaining Worldwide Recognition

SAN DIEGO and NEWARK, Del., April 28, 2026 /PRNewswire/ -- Recently, ACROBiosystems was honored as a "Protein Supplier to Watch in Cancer Research in 2026" at the CiteAb Awards. CiteAb accelerates scientific research by providing a search engine and data services, and its awards leverage high-qu...

2026-04-28 23:00 4480

Natural Field Releases Research Findings on NFTriSolve® Co-Loading Liposome Formula

XI'AN, China, April 28, 2026 /PRNewswire/ -- Natural Field announced that the latest research and development breakthrough of the NFTriSolve® co-loading liposome technology has been achieved. Through a comparison of different formulations and processes in a zebrafish experiment, the research resu...

2026-04-28 22:59 5122
1 ... 16171819202122 ... 261